NEI Podcast podcast

E126 - 2021 NEI Congress Extended Q&A Podcast: Female Mental Health Issues with Dr. Manpreet Singh

0:00
19:19
Spola tillbaka 15 sekunder
Spola framåt 15 sekunder
In this episode, Dr. Manpreet Singh answers your unaddressed questions from her presentation: It's a Woman's World: Exploring Female Mental Health Issues at the 2021 NEI Congress.    Dr. Manpreet K. Singh is Associate Professor of Psychiatry and Behavioral Sciences, and leads a program aimed to accelerate understanding and treatment in youth with or at high risk for developing lifelong mood disorders.Dr. Singh earned her MD at Michigan State University and her MS at University of Michigan. She completed her combined residency training in Pediatrics, Psychiatry, and Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center. After two years of T32 postdoctoral training at Stanford’s Center for Interdisciplinary Brain Sciences Research, she joined the faculty in 2009.   Dr. Singh leads a multidisciplinary team that evaluates and treats youth with a spectrum of mood disorders as young as age 2 and well into their 20s. Her NIMH and industry funded studies examine mechanisms underlying mood disorders and apply cutting edge strategies to directly modulate the brain using transcranial magnetic stimulation and real time neurofeedback. She is also investigating the efficacy and safety of pharmacotherapies and psychotherapies, such as family focused psychotherapy and mindfulness meditation, to reduce mood symptoms and family stress. All of these areas of research aim to elucidate core mechanisms underlying mood disorders and how treatment early in life can pave the path to more adaptive outcomes.

Fler avsnitt från "NEI Podcast"

  • NEI Podcast podcast

    E135 - (CME) The Art of Switching Antipsychotics to Better Treat Patients with Schizophrenia

    56:15

    In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl on best practices for switching antipsychotics. Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click: https://nei.global/POD22-Switch Learning Objectives: After completing this educational activity, you should be better able to: Understand the relevance of receptor binding properties and pharmacokinetic profiles when switching antipsychotics Follow evidence-based guidelines when switching antipsychotics Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.  NEI designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest score of 70% or higher is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics.  Credit Types. The following are being offered for this activity: Nurse Practitioner (ANCC): contact hours Pharmacy (ACPE): knowledge-based contact hours   Physician (ACCME): AMA PRA Category 1 Credits ™ Physician Assistant (AAPA): Category 1 CME credits Psychology (APA): CE credits Social Work (ASWB-ACE): ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™ Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity. Disclosures: All individuals in a position to influence or control content are required to disclose all relevant financial relationships, which were then mitigated prior to the activity being presented. Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris Interviewee Stephen M. Stahl, MD, PhD, DSc (Hon.)  Clinical Professor, Department of Psychiatry and Neuroscience, University of California, Riverside School of Medicine, Riverside, CA Adjunct Professor, Department of Psychiatry, University of California, San Diego School of Medicine, La Jolla, CA Honorary Visiting Senior Fellow, University of Cambridge, Cambridge, UK Director of Psychopharmacology Services, California Department of State Hospitals, Sacramento, CA Grant/Research: Acadia, Avanir, Braeburn, Intra-Cellular, Ironshore, Lilly, Neurocrine, Otsuka, Shire, Sunovion Consultant/Advisor: AbbVie, Acadia, Alkermes, Allergan, Arbor, Axovant, Axsome, Celgene, ClearView, Concert, EMD Serono, Eisai, Ferring, Impel, Intra-Cellular, Ironshore, Janssen, Karuna, Lilly, Lundbeck, Merck, Otsuka, Pfizer, Relmada, Sage, Servier, Shire, Sunovion, Takeda, Taliaz, Teva, Tonix, Tris, Vifor Speakers Bureau: Acadia, Lundbeck, Otsuka, Perrigo, Servier, Sunovion, Takeda, Teva, Vertex Board Member: Genomind Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose. The Planning Committee and Peer Reviewer have no financial relationships to disclose. Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses. Cultural Linguistic Competencies and Implicit Bias: A variety of resources addressing cultural and linguistic competencies and implicit bias can be found in this downloadable handout. Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies. Released: January 26, 2022          CE credit expires: January 26, 2025          
  • NEI Podcast podcast

    E134 - The PsychopharmaStahlogy Show: The Power of Dark Persuasion with Dr. Joel Dimsdale

    49:18

    How did you come about writing “Dark Persuasion”? What exactly is brainwashing? What are the common features of torture and coercive persuasion? In this episode, Dr. Andrew Cutler interviews Dr. Joel Dimsdale about his new book, “Dark Persuasion”. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: The Power of Dark Persuasion with Dr. Joel Dimsdale Part 2: Dark Psychiatry and Social Media with Dr. Donatella Marazziti Part 3: Good and Bad Neuroplasticity Subscribe to the NEI Podcast, so that you don’t miss another episode!
  • NEI Podcast podcast

    Missa inte ett avsnitt av NEI Podcast och prenumerera på det i GetPodcast-appen.

    iOS buttonAndroid button
  • NEI Podcast podcast

    E133 - Seasonal Affective Disorder (SAD)

    37:57

    What exactly is seasonal affective disorder (SAD)? What are some of the most common symptoms?  In this episode, Dr. Jade Wu addresses these questions and much more about SAD. Jade Wu, PhD, DBSM, is a Board-certified behavioral sleep medicine specialist and researcher at Duke University School of Medicine. Her current research focuses on treating sleep disorders in those with chronic illness. She is a frequent guest on popular TV, radio and podcast shows like NPR and ABC, and her work is featured in publications like New York Times and Huffington Post. She formerly hosted the popular Savvy Psychologist podcast. Dr. Wu’s mission is to spread the gift of sleep, so that people can be their healthiest, organizations can be their most innovative, and societies can sleep their way towards justice and healing.
  • NEI Podcast podcast

    E132 - (CME) Monitoring and Managing Metabolic Side Effects

    1:00:40

    In this episode, Dr. Andrew Cutler interviews Dr. Joseph Goldberg on the management of metabolic side effects associated with antipsychotics.  Optional CME/CE Credits and Certificate Instructions: After listening to the podcast, to take the optional posttest and receive CME/CE credit, click https://nei.global/POD21-MET  Learning Objectives: After completing this educational activity, you should be better able to: Differentiate antipsychotic medications based on risk for metabolic side effects Monitor patients for metabolic side effects Implement management strategies to address metabolic side effects  Accreditation: In support of improving patient care, Neuroscience Education Institute (NEI) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.   NEI designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit ™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.  A posttest minimum score of 70% is required to receive CME/CE credit. The content in this activity pertains to pharmacology and is worth 1.0 continuing education hour of pharmacotherapeutics Credit Types. The following are being offered for this activity: Nurse Practitioner (ANCC): contact hours Pharmacy (ACPE): application-based contact hours Physician (ACCME): AMA PRA Category 1 Credits ™ Physician Assistant (AAPA): Category 1 CME credits Psychology (APA): CE credits Social Work (ASWB-ACE): ACE CE credits Non-Physician Member of the Healthcare Team: Certificate of Participation stating the program is designated for AMA PRA Category 1 Credits ™  Peer Review: The content was peer-reviewed by an MD specializing in psychiatry to ensure the scientific accuracy and medical relevance of information presented and its independence from bias. NEI takes responsibility for the content, quality, and scientific integrity of this CME/CE activity.  Disclosures: All individuals in a position to influence or control content were required to disclose any relevant financial relationships, which were then mitigated prior to the activity being presented.  Interviewer Andrew J. Cutler, MD Clinical Associate Professor, Department of Psychiatry, SUNY Upstate Medical University, Syracuse, NY Chief Medical Officer, Neuroscience Education Institute, Carlsbad, CA Consultant/Advisor: AbbVie, Acadia, AiCure, Alfasigma, Alkermes, Allergan, Atentiv, Cognitive Research, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sage, Sunovion, Supernus, Takeda, Teva Speakers Bureau: AbbVie, Acadia, Alkermes, Allergan, Intra-Cellular, Ironshore, Janssen, Lundbeck, Neurocrine, Noven, Otsuka, Sunovion, Supernus, Takeda, Teva, Tris  Interviewee Joseph F. Goldberg, MD   Clinical Professor, Department of Psychiatry, Icahn School of Medicine at Mount Sinai, New York City, NY Consultant/Advisor: BioXcel, Intra-Cellular, Lundbeck, Otsuka, Sunovion Speakers Bureau: Allergan/Abbvie, Intra-Cellular, Sage, Sunovion Royalties: American Psychiatric Publishing, Cambridge University Press Pre-Interview Author Sabrina K. Bradbury-Segal, PhD Medical Writer, Neuroscience Education Institute, Carlsbad, CA No financial relationships to disclose.  The Planning Committee and Peer Reviewer have no financial relationships to disclose.  Disclosure of Off-Label Use: This educational activity may include discussion of unlabeled and/or investigational uses of agents that are not currently labeled for such use by the FDA. Please consult the product prescribing information for full disclosure of labeled uses.  Cultural and Linguistic Competency: A variety of resources addressing cultural and linguistic competency can be found here: https://nei.global/culture  Support: This activity is supported by an unrestricted educational grant from Intra-Cellular Therapies.  Released: December 22, 2021          CE credit expires: December 22, 2024    
  • NEI Podcast podcast

    E131 - The Future of Psychopharmacology

    52:30

    Can you explain how the same symptoms may cut across numerous psychiatric disorders and how the same treatment may be efficacious across psychiatric disorders? What areas in psychopharmacology remain the most challenging to treat and why do you think that is? In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl about the future of psychopharmacology. With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: What’s New in the Fifth Edition of Stahl’s Essential Psychopharmacology? Part 2: The Fifth Edition Video Series and How to Implement the Best Learning Strategies for Understanding Psychopharmacology Part 3: The Future of Psychopharmacology Subscribe to the NEI Podcast, so that you don’t miss another episode!
  • NEI Podcast podcast

    E130 - Therapeutics in the Digital Age: Redefining Care with Software-Based Medicines

    58:55

    Who is Pear and what are prescription digital therapeutics? Why are PDTs so important to the continuum of care, especially when it comes to mental health? In this fascinating interview, Dr. Andrew Cutler interviews Dr. Corey McMann, the President and CEO of Pear Therapeutics about the importance of this technology in treating mental health. Corey M. McCann, MD, PhD, is the President and CEO of Pear Therapeutics. Previously, Corey was an investor with MPM Capital, where he evaluated new healthcare investment opportunities, managed relationships with strategic partners, and oversaw strategy and execution at portfolio companies. Prior to MPM, he was an Engagement Manager with McKinsey & Company, where he advised pharmaceutical, medical device, and biotechnology companies on the acquisition, development, and commercialization of life science technologies. He led McKinsey’s central nervous system expertise group, advising clients across the healthcare value chain.
  • NEI Podcast podcast

    E129 - A Look Back at This Year in Psychopharmacology with Dr. Andy Cutler

    1:03:35

    What are some of the new FDA approvals for medications that happened this year? What did we learn about the association between ADHD and Alzheimer’s disease from a nationwide cohort study that was conducted? In this important and timely episode, Dr. Andrew Cutler addresses these questions and many more on the most interesting updates in psychopharmacology in 2021. Dr. Andrew Cutler is the Chief Medical Officer (CEO) at the Neuroscience Education Institute (NEI). Dr. Cutler has deeply rooted knowledge in clinical experience, academic experience, and emerging science in psychiatry through clinical trials. He also worked closely with federal regulators and legislators to advocate for improved mental health care as part of the Clinton health care reform effort, leading to the Mental Health Parity Act of 1996. Among his notable leadership positions, Dr. Cutler is currently Clinical Associate Professor of Psychiatry, SUNY Upstate Medical University and previously served as Courtesy Assistant Professor of Psychiatry at University of Florida, and has been the principal investigator on more than 400 psychiatric and medical clinical trials. Dr. Cutler received a BS in biology from Haverford College in Philadelphia, and then received his medical degree from the University of Virginia School of Medicine, where he was elected to Alpha Omega Alpha honor medical society. He completed his medical internship, internal medicine residency, and psychiatry residency at the University of Virginia, where he served as Chief Resident of Psychiatric Medicine. Dr. Cutler then served as Assistant Professor and Director of Psychiatric Medicine at the University of Chicago. He is board certified in internal medicine and psychiatry. Resources: This Month in Psychopharmacology: https://www.neiglobal.com/Members/MonthInPsychopharmNew/tabid/508/Default.aspx FDA Clears Technology to Aid in Concussion Diagnosis: https://www.neiglobal.com/Members/MonthInPsychopharmPost/tabid/509/Default.aspx?topic=20527 International League Against Epilepsy Society (AES): https://www.ilae.org/
  • NEI Podcast podcast

    E128 - The Fifth Edition Video Series and How to Implement the Best Learning Strategies for Understanding Psychopharmacology

    35:54

    What was the inspiration behind creating the Fifth Edition video series? What are your best learning strategies for studying psychopharmacology? In this episode, Dr. Andrew Cutler interviews Dr. Stephen Stahl about the Fifth Edition Video Series and about the most effective learning strategies for psychopharmacology! With this special series, brought to you by the NEI Podcast we will address a different theme in psychopharmacology every 3 months. Each theme is split into 3 parts, with one part released each month. This theme is on practical psychopharmacology. Episodes to be released under this theme include: Part 1: What’s New in the Fifth Edition of Stahl’s Essential Psychopharmacology? Part 2: The Fifth Edition Video Series and How to Implement the Best Learning Strategies for Understanding Psychopharmacology Part 3: The Future of Psychopharmacology Subscribe to the NEI Podcast, so that you don’t miss another episode!
  • NEI Podcast podcast

    E127 - 2021 Congress Extended Q&A Podcast: Obsessive-Compulsive Disorder with Dr. Jeffrey Strawn

    11:14

    In this episode, Dr. Jeffrey Strawn addresses your unanswered questions from his presentation: Re-Counting Neurobiological Treatment Advances of Obsessive-Compulsive Disorder.    Dr. Jeffrey R. Strawn's early work examined the neurophysiology, neurochemistry and neuroanatomy of anxiety disorders in children and adolescents.In parallel with Dr. Strawn's work on the neurophysiology of mood and anxiety disorders in children and adolescents, he has worked to increase the evidence base for treatment interventions in youth. Using meta-analysis, he demonstrated that antidepressants are well-tolerated in pediatric patients with anxiety disorders, but also examined specific class-specific side effects (e.g., activation). Also, he has examined the unique tolerability of antidepressants in special populations of adolescents with depressive and anxiety disorders (e.g., those who are at high risk for the development of bipolar disorder) and has observed that antidepressants are poorly tolerated in this population with likelihood of antidepressant adverse events leading to discontinuation being directly related to age. Additionally, he has extensive expertise in the conduct of double blind, placebo-controlled trials in youth with anxiety disorders. 
  • NEI Podcast podcast

    E126 - 2021 NEI Congress Extended Q&A Podcast: Female Mental Health Issues with Dr. Manpreet Singh

    19:19

    In this episode, Dr. Manpreet Singh answers your unaddressed questions from her presentation: It's a Woman's World: Exploring Female Mental Health Issues at the 2021 NEI Congress.    Dr. Manpreet K. Singh is Associate Professor of Psychiatry and Behavioral Sciences, and leads a program aimed to accelerate understanding and treatment in youth with or at high risk for developing lifelong mood disorders.Dr. Singh earned her MD at Michigan State University and her MS at University of Michigan. She completed her combined residency training in Pediatrics, Psychiatry, and Child and Adolescent Psychiatry at Cincinnati Children’s Hospital Medical Center. After two years of T32 postdoctoral training at Stanford’s Center for Interdisciplinary Brain Sciences Research, she joined the faculty in 2009.   Dr. Singh leads a multidisciplinary team that evaluates and treats youth with a spectrum of mood disorders as young as age 2 and well into their 20s. Her NIMH and industry funded studies examine mechanisms underlying mood disorders and apply cutting edge strategies to directly modulate the brain using transcranial magnetic stimulation and real time neurofeedback. She is also investigating the efficacy and safety of pharmacotherapies and psychotherapies, such as family focused psychotherapy and mindfulness meditation, to reduce mood symptoms and family stress. All of these areas of research aim to elucidate core mechanisms underlying mood disorders and how treatment early in life can pave the path to more adaptive outcomes.

Kom åt alla poddsändningar i gratisappen GetPodcast.

Prenumerera på dina favoritpoddar, lyssna på avsnitt offline och få spännande rekommendationer.

iOS buttonAndroid button